A DNA gene chip, also called as DNA microarray or DNA chip can be resembled with a computer chip. The difference between the two is that a computer chip is composed of electronic circuit whereas a DNA gene chip is composed of DNA molecules. It can also be stated that DNA gene chip is a collection of DNA spots that are embedded on solid surface. A DNA gene chip is about the size of a postage stamp. This technology has become very popular in drug discovery and medical research sector as it significantly brings down research time. DNA gene chip plays a vital role in helping medical researchers to simultaneously measure the expression levels of several thousands of genes. The spiraling popularity of DNA chips has prompted many new players to enter the market and profit from their growing demand. In view of these aspects, the market for DNA gene chips is projected to show double-digit growth during the forecast period. This technology is used to measure the expression levels of thousands of gene together at the same time.
Based on type, DNA gene chip market can be segmented as oDNA (oligonucleotide DNA) and cDNA (complementary DNA). The former is a dominant segment in the market, accounting for larger share of the overall market. The DNA gene chip market can also be classified by application as: comparative genomic hybridization, gene expression profiling, geneID, and others. The gene expression market emerges as the largest application segment owing to its extensive utilization in agriculture, clinical diagnostics, and other emerging sectors. This segment will likely demonstrate healthy growth over the forecast period as a result of substantial funding from governments and private players alike.
Growth in personalized medicines, rising prevalence of cancer, technology advancements and large scale initiatives by the organization are some of the major drivers of this market. According to the World Health Organization (WHO) worldwide 8.2 million people died of cancer in 2012. In 2013, American Cancer Society (ACS) published that, around 300,000 men and 276,000 women died due to cancer in 2012 in the U.S. Moreover, California Journal of Clinical Cancer (CJCC) stated that, one in the every six U.S. men have received diagnosis test for prostate cancer at some point in their lives. Hence, such high prevalence of diseased condition would raise the growth of the market to a higher end.
The report studies the DNA gene chip market based on geography by classifying it as: North America, Europe, Asia-Pacific, and Rest of the World. North America dominates the global market for DNA gene chip due to growing demand of gene chip technology in this region. Moreover, technological advancement in DNS gene chip is also accentuating the market growth in North American region. On the other hand, aggressive growth in Asian economies such as China, Singapore, India, and South Korea will lead to a shift in the dynamics of the DNA gene chip market. These markets are poised for massive growth as drug discovery and clinical trials intensify here.
Some of the majors players of the DNA gene chip market include Affymetrix, Inc., Agilent Technologies, Biomérieux Sa, Biometrix Technology Inc, Capitalbio Corporation, Bioneer Corporation, Eurofins Mwg Operon, Illumina Inc., Greiner Bio-One, Lc Sciences, Life Technologies Corporation, Microarrays Inc, Macrogen Inc, Sequenom Inc, Scienion Ag, Sigma-Aldrich Corporation, Savyon Diagnostics Ltd, Roche Nimblegen Inc, Wafergen Biosystems Inc and others.